Healthy “Unexpected” Health Benefits for Treatments for Diabetes and Weight Loss

A scientific study has revealed unexpected benefits to human health, from medicines mainly used to treat diabetes, obesity patients and weight loss. The study, conducted by the George Institute of International Health, and published in the journal “Lancet: Diabetes and Endocrinology”, highlights new benefits of GLP-1 receptors, as it has shown a significant reduction in renal weakening and failure, as well as the heart and blood vessels, and reduced the risk of stripes. GLP-1 receptors were mainly developed for type 2 diabetes as it simulates a hormone effect that increases insulin production, reduces blood sugar levels, and recently these drugs have become an effective option to treat obesity by delaying digestion, the feeling of saturation and reducing appetite. The lead author of the study, Sunil Badivi, a faculty member at George International Health Institute, and New South University in Sydney, said that the study expanded the current knowledge of this category of medicine in the main areas, including the benefits in people with chronic kidney disease, people with diabetes, and those. The prevention of the decline of kidney function and the researchers analyzed 11 clinical experiments, including more than 85 thousand participants, including about 67,000 type 2 diabetes, and about 17 thousand suffering from obesity, or heart disease without diabetes. The study included well -known medicines, such as those containing the active substance known as semaglotide – mugayy and ozmbek – and the medicine containing the active substance deleglotide – Troldy – and the medicines containing the material to largenlotide – Vitcuma. The study showed that the GLP-1 receptors reduced the risk of renal failure by 16%, the decline of kidney function by 22%, the risk of death caused by kidney disease and the decline of its functions by 19%. It is not known that the biological mechanisms behind this unexpected benefit, but the GLP-1 receptors lowers the blood sugar levels by stimulating insulin secretion, and the secretion of glucagon, a hormone that increases sugar levels. By lowering these levels, it reduces medication from the possibility of kidney function. Previous studies have shown that GLP-1 opponents have anti-inflammatory and oxidant characteristics, which are factors that negatively affect the kidneys and heart, and by reducing inflammation and oxidation, this medicine protects kidney cells and reduces the decline of their functions in the long run. The GLP-1 receptors seem to improve the blood flow to the kidneys through its positive effects on the blood vessels, which helps maintain blood filtration, cleans it better from toxins and reduces the risk of kidney failure. Reducing blood pressure and high blood pressure is one of the most important causes of the deterioration of the kidney function, and it has been proven that this medication has the ability to slightly lower blood pressure, which protects the kidneys from the damage caused by excess pressure. Studies show that the GLP-1 bars help reduce the amount of protein leaked, suggesting that it is the role of protecting the structure and tissues of the kidneys. The study also confirmed previous results that this medicine reduced the risk of heart death, heart attacks and strokes by 14%, while the public mortality rate fell by 13%. The GLP-1 risks improve the elasticity of blood vessels, reducing the accumulation of fats in it, which increases blood flow and protects the kidneys. The study is the first of its kind to show a clear effect of this medicine in reducing the risk of renal failure, or kidney disease in the final stages. The treatment of kidney and heart disease and results shows a significant role of this medication in the protection of the kidneys and heart for patients with common diseases, such as diabetes, obesity and heart and kidney disease. The results can make a qualitative shift in medical leadership to treat kidney and heart disease, contributing to the reduction of the burden of non -infected diseases worldwide. The prevalence of chronic kidney disease is estimated by one person in the world, or about 850 million people. Kidney disease is the tenth cause of death in the world, with the expectation that it will become the fifth cause by 2050. With risk factors such as diabetes, obesity and heart disease, these conditions are a major health burden. The study highlights the importance of expanding the use of GLP-1 receptors in clinical practices to improve the lives of patients and reduce the cost of healthcare.